Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The debt to assets ratio is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
DEBT TO ASSETS RATIO
0.00%
DEBT TO ASSETS RATIO AVG TTM
0.00%
DEBT TO ASSETS RATIO AVG 3Y
0.00%
DEBT TO ASSETS RATIO AVG 5Y
0.00%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Nuvectis Pharma, Inc.
Market Cap
$533.69M
Debt to Assets Ratio
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$534.35M
Debt to Assets Ratio
0.51%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$536.29M
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$526.68M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$524.77M
Debt to Assets Ratio
0.19%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$543.14M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$521.64M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | $533.69M | 0.00% | 0.00% | 0.00% | 0.00% |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $534.35M | 0.51% | N/A | N/A | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $536.29M | 0.02% | N/A | N/A | N/A |
| ProKidney Corp. (PROK)vs › | $538.01M | 0.01% | N/A | N/A | N/A |
| Immix Biopharma, Inc. (IMMX)vs › | $526.68M | 0.00% | N/A | N/A | N/A |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $524.77M | 0.19% | N/A | N/A | N/A |
| Shattuck Labs, Inc. (STTK)vs › | $543.14M | 0.01% | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $522.16M | 0.07% | N/A | N/A | N/A |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $521.64M | 0.00% | N/A | N/A | N/A |
| Monopar Therapeutics Inc. (MNPR)vs › | $546.94M | 0.00% | N/A | N/A | N/A |
Debt/Assets
0.0%
Debt/Equity
0.00
Current Ratio
1.68
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
